Patients who have atrial fibrillation have an approximately 5-fold risk of suffering a stroke.  Even those patients who survive a stroke can often suffer significant life-altering disability. Strokes that occur with atrial fibrillation are typically due to clots that form in the left atrial appendage (LAA).  The typical standard of care is to use blood thinners or anticoagulants such as Warfarin, or other such agents, to prevent clot formation. However, in those patients with non-valvular atrial fibrillation who have a higher risk of stroke and yet who cannot take anticoagulation, the FDA has approved the Watchman Left Atrial Appendage Closure (LAAC) Device, to close off the left atrial appendage and preclude the need for long term anticoagulation.  This procedure is performed entirely via the Femoral vein. Cardiac Specialists physicians Murali Chiravuri, Robert Winslow, and Ari Pollack are part of the team working with the Yale team of physicians to implant Watchman devices.